Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 2
2013 2
2015 1
2016 2
2017 1
2018 1
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

9 results
Results by year
Filters applied: . Clear all
Page 1
The role of immune semaphorins in cancer progression.
Eissler N, Rolny C. Eissler N, et al. Exp Cell Res. 2013 Jul 1;319(11):1635-43. doi: 10.1016/j.yexcr.2013.04.016. Epub 2013 May 18. Exp Cell Res. 2013. PMID: 23693019 Review. No abstract available.
Inhibition of Microsomal Prostaglandin E Synthase-1 in Cancer-Associated Fibroblasts Suppresses Neuroblastoma Tumor Growth.
Kock A, Larsson K, Bergqvist F, Eissler N, Elfman LHM, Raouf J, Korotkova M, Johnsen JI, Jakobsson PJ, Kogner P. Kock A, et al. Among authors: eissler n. EBioMedicine. 2018 Jun;32:84-92. doi: 10.1016/j.ebiom.2018.05.008. Epub 2018 May 24. EBioMedicine. 2018. PMID: 29804818 Free PMC article.
Potent CD4+ T cell-associated antitumor memory responses induced by trifunctional bispecific antibodies in combination with immune checkpoint inhibition.
Deppisch N, Ruf P, Eißler N, Lindhofer H, Mocikat R. Deppisch N, et al. Among authors: eissler n. Oncotarget. 2017 Jan 17;8(3):4520-4529. doi: 10.18632/oncotarget.13888. Oncotarget. 2017. PMID: 27966460 Free PMC article.
Targeting Suppressive Myeloid Cells Potentiates Checkpoint Inhibitors to Control Spontaneous Neuroblastoma.
Mao Y, Eissler N, Blanc KL, Johnsen JI, Kogner P, Kiessling R. Mao Y, et al. Among authors: eissler n. Clin Cancer Res. 2016 Aug 1;22(15):3849-59. doi: 10.1158/1078-0432.CCR-15-1912. Epub 2016 Mar 8. Clin Cancer Res. 2016. PMID: 26957560 Free article.
Regulation of myeloid cells by activated T cells determines the efficacy of PD-1 blockade.
Eissler N, Mao Y, Brodin D, Reuterswärd P, Andersson Svahn H, Johnsen JI, Kiessling R, Kogner P. Eissler N, et al. Oncoimmunology. 2016 Sep 9;5(12):e1232222. doi: 10.1080/2162402X.2016.1232222. eCollection 2016. Oncoimmunology. 2016. PMID: 28123870 Free PMC article.
Efficacy and Tolerability of a GD2-Directed Trifunctional Bispecific Antibody in a Preclinical Model: Subcutaneous Administration Is Superior to Intravenous Delivery.
Deppisch N, Ruf P, Eissler N, Neff F, Buhmann R, Lindhofer H, Mocikat R. Deppisch N, et al. Among authors: eissler n. Mol Cancer Ther. 2015 Aug;14(8):1877-83. doi: 10.1158/1535-7163.MCT-15-0156. Epub 2015 Jun 10. Mol Cancer Ther. 2015. PMID: 26063765 Free article.
Potential of the trifunctional bispecific antibody surek depends on dendritic cells: rationale for a new approach of tumor immunotherapy.
Eissler N, Mysliwietz J, Deppisch N, Ruf P, Lindhofer H, Mocikat R. Eissler N, et al. Mol Med. 2013 Apr 30;19(1):54-61. doi: 10.2119/molmed.2012.00140. Mol Med. 2013. PMID: 23552725 Free PMC article.
Trifunctional bispecific antibodies induce tumor-specific T cells and elicit a vaccination effect.
Eissler N, Ruf P, Mysliwietz J, Lindhofer H, Mocikat R. Eissler N, et al. Cancer Res. 2012 Aug 15;72(16):3958-66. doi: 10.1158/0008-5472.CAN-12-0146. Epub 2012 Jun 28. Cancer Res. 2012. PMID: 22745368 Free article.
Ganglioside GD2-specific trifunctional surrogate antibody Surek demonstrates therapeutic activity in a mouse melanoma model.
Ruf P, Schäfer B, Eissler N, Mocikat R, Hess J, Plöscher M, Wosch S, Suckstorff I, Zehetmeier C, Lindhofer H. Ruf P, et al. Among authors: eissler n. J Transl Med. 2012 Nov 7;10:219. doi: 10.1186/1479-5876-10-219. J Transl Med. 2012. PMID: 23134699 Free PMC article.